Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age. Insulin resistance/hyperinsulinemia is a prevalent finding in women with PCOS, which indicates that insulin resistance/hyperinsulinemia may be an important player in the pathogenesis of the PCOS. However, the underlying mechanism of insulin resistance/hyperinsulinemia on the pathogenesis of the PCOS remains elusive. In this study, we found an increased high-mobility group box 1 (HMGB1) in the serum from women with PCOS having insulin resistance/hyperinsulinemia. Furthermore, we discovered that high concentration of insulin, which mimics insulin resistance model, promoted apoptosis in primary cultured rat ovarian granulosa cells (GCs) via its effect on the increase in extracellular HMGB1. Our data presented the first evidence that increased HMGB1 induced by insulin resistance/hyperinsulinemia promoted apoptosis of ovarian GCs, which provided new molecular basis for the PCOS pathogenesis.
FauserBCTarlatzisBCRebarRW. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3 rd PCOS consensus workshop group. Fertility Steril. 2012;97(1):28–38. e25.
2.
Diamanti-KandarakisEDunaifA. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Rev. 2012;33(6):981–1030.
3.
GoudasVTDumesicDA. Polycystic ovary syndrome. Endocrinology and metabolism clinics of North America. Dec 1997;26(4):893–912.
4.
Diamanti-KandarakisEPiperiCArgyrakopoulouG. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens). 2006;5(1):17.
5.
TaylorSIDonsRFHernadezERothJGordenP. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Int Med. 1982;97(6):851–855.
6.
CataldoNADumesicDAGoldsmithPCJaffeRB. Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis. Hum Reprod. 2000;15(9):1889–1897.
7.
ZhangJZhuGWangXXuBHuL. Apoptosis and expression of protein TRAIL in granulosa cells of rats with polycystic ovarian syndrome. J Huazhong Univ Sci Technol. 2007;27(3):311–314.
8.
DasuMRDevarajSParkSJialalI. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33(4):861–868.
9.
HagiwaraSIwasakaHHasegawaAKogaHNoguchiT. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med. 2008;36(8):2407–2413.
10.
KimSWLimCMKimJB. Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res. 2011;20(2):159–169.
11.
XuHYaoYSuZ. Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am J Physiol Heart Circ Physiol. 2011;300(3):H913–H921.
12.
LujanMEChizenDRPiersonRA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008;30(8):671–679.
13.
FedorcsákPDalePOStorengRTanboTÅbyholmT. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod. 2001;16(6):1086–1091.
14.
LiuJParkE-SJoM. Runt-related transcription factor 1 regulates luteinized hormone-induced prostaglandin-endoperoxide synthase 2 expression in rat periovulatory granulosa cells. Endocrinol. 2009;150(7):3291–3300.
15.
LingHYHuBHuXB. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes. 2012;120(9):553–559.
16.
L iCGNingGChenJH. Establishing and identifing insulin-resistance HepG2 cell line. Chin J Diabetes. 1999;7(4):198–200.
17.
Diamanti-KandarakisEAlexandrakiKProtogerouA. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152(5):749–756.
18.
PoretskyLCataldoNARosenwaksZGiudiceLC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20(4):535–582.
19.
RosenfieldRL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol. 2001;45(3):S95–S104.
20.
JakubowiczDJNestlerJE. 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab. 1997;82(2):556–560.
21.
NelsonVLLegroRSStraussJFIIIMcAllisterJM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13(6):946–957.
22.
Diamanti-KandarakisEPapavassiliouAG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12(7):324–332.
23.
Garcia-MonzonCLo IaconoOMayoralR. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol. 2011;54(1):142–152.
24.
JiangYPagadalaJMillerDSteinleJJ. Reduced insulin receptor signaling in retinal Müller cells cultured in high glucose. Mol Vis. 2013;19:804.
25.
NavarroPValverdeAMBenitoMLorenzoM. Insulin/IGF-I rescues immortalized brown adipocytes from apoptosis down-regulating Bcl-xS expression, in a PI 3-kinase-and map kinase-dependent manner. Exp Cell Res. 1998;243(2):213–221.
26.
ŠtrosMOzakiTBačíkováAKageyamaHNakagawaraA. HMGB1 and HMGB2 cell-specifically down-regulate the p53-and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem. 2002;277(9):7157–7164.
27.
YangHHreggvidsdottirHSPalmbladK. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci. 2010;107(26):11942–11947.
28.
ScaffidiPMisteliTBianchiME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.
29.
YanXXLuLPengWH. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. 2009;205(2):544–548.
